Unique ID issued by UMIN | UMIN000047622 |
---|---|
Receipt number | R000054229 |
Scientific Title | Real World Outcome Analysis for APAC High Risk Localized Prostate Cancer Patients Treated With Radical Prostatectomy and Perioperative Hormonal Therapy |
Date of disclosure of the study information | 2022/05/01 |
Last modified on | 2023/05/02 09:27:03 |
Real World Outcome Analysis for APAC High Risk Localized Prostate Cancer Patients Treated With Radical Prostatectomy and Perioperative Hormonal Therapy
ACE Study
Real World Outcome Analysis for APAC High Risk Localized Prostate Cancer Patients Treated With Radical Prostatectomy and Perioperative Hormonal Therapy
ACE Study
Japan | Asia(except Japan) |
High Risk Localized Prostate Cancer
Urology |
Malignancy
NO
Describe real-world clinical characteristics, treatment pathways, and outcomes in HR LPC patients from Japan, South Korea, and Taiwan
Safety,Efficacy
Among HR LPC patients following RP and perioperative hormonal therapies:
Evaluate the yearly conditional prostate-specific antigen (PSA) progression-free survival probabilities over 5 years
Among HR LPC patients following RP and perioperative hormonal therapies:
Secondary objective #1: Describe patient characteristics (including stage at diagnosis and time from diagnosis to RP)
Secondary objective #2: Describe treatments provided with RP and following RP including:
a.Treatments received (RP and neo-adjuvant hormonal therapy only, RP and adjuvant hormonal therapy only, or RP and both neo-adjuvant and adjuvant hormonal therapies)
b.Hormonal therapy duration
Secondary objective #3: Evaluate the yearly local or distant radiographic progression-free survival probabilities over 5 years
Exploratory objective #1 (if data permits): Evaluate median time to PSA progression
Exploratory objective #2 (if data permits): Describe rate of pathologic complete response (pCR) in HR LPC patients who received RP and:
a.neoadjuvant hormonal therapy only
b.adjuvant hormonal therapy only
c.both neoadjuvant and adjuvant hormonal therapies
Exploratory objective #3 (if data permits): Describe rate of negative margin in HR LPC patients who received RP and:
a.neoadjuvant hormonal therapy only
b.adjuvant hormonal therapy only
c.both neoadjuvant and adjuvant hormonal therapies
Exploratory objective #4 (if data permits): Describe rate of HR LPC patients receiving RP and hormonal therapies among:
a.newly diagnosed HR LPC patients
b.newly diagnosed HR LPC patients who received RP
Observational
18 | years-old | <= |
Not applicable |
Male
1.>=18 years of age at time of LPC diagnosis
2.Histologically confirmed adenocarcinoma of the prostate
3.Newly diagnosed between 1 January 2015 to 30 June 2017 (both dates inclusive)
4.High risk localized prostate cancer, as defined by NCCN prostate cancer guideline (2020 version 1)
5.Must have received radical prostatectomy between 1 January 2015 and 30 June 2017
6.Must have received at least 1 perioperative hormonal therapy pattern:
a.>=3 months neoadjuvant hormonal therapy, duration between date of last dose and date of RP should be <=2 months; AND / OR
b.>=6 months adjuvant hormonal therapy, first dose started within 6 months of RP surgery
Distant metastasis based on conventional imaging (clinical stage M1) at time of prostate cancer diagnosis
600
1st name | Anildeep |
Middle name | |
Last name | Singh |
Regional Medical Affairs
Regional Medical Affairs
118222
2 Science Park Drive, #07-13, Ascent, Singapore
+60(3)76614603
asingh15@its.jnj.com
1st name | Maki |
Middle name | |
Last name | Hosokawa |
IQVIA Services Japan K.K.
Real World Evidence Services
1080074
Keikyu Dai-1 Building 4-10-18 Takanawa, Minato-ku, Tokyo
08040924367
Maki.Hosokawa@iqvia.com
Johnson & Johnson International (Singapore) Pte. Ltd.
Johnson & Johnson International (Singapore) Pte. Ltd.
Profit organization
NPO MINS Ethics Committee
2F, ST Shibuya Building 15-14 Dogenzaka, Shibuya-ku, Tokyo
0364161868
npo-mins@j-irb.com
NO
2022 | Year | 05 | Month | 01 | Day |
Unpublished
77
No longer recruiting
2021 | Year | 11 | Month | 15 | Day |
2022 | Year | 06 | Month | 02 | Day |
2022 | Year | 06 | Month | 30 | Day |
2023 | Year | 06 | Month | 30 | Day |
2023 | Year | 06 | Month | 30 | Day |
2023 | Year | 06 | Month | 30 | Day |
This is a real world, retrospective cohort study for HR LPC patients from Japan, South Korea and Taiwan.
Electronic medical record (EMR) databases from selected Korean medical centers and multi-hospital databases in Taiwan will be analyzed to produce aggregated country-level outputs. In parallel, a chart review will be conducted at selected tertiary hospitals in Japan to develop a study-specific database. The statistical outputs from the Japan study-specific database will be meta-analyzed with the country-level outputs from South Korea and Taiwan to produce a study report.
This study population includes newly diagnosed adult HR LPC patients with follow-up until 30 June 2022.
2022 | Year | 04 | Month | 28 | Day |
2023 | Year | 05 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000054229
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |